Patients with advanced cancer often have no access to potentially effective targeted drugs, despite expressing a known biomarker of a marketed drug. However, if the agent is not licensed for that particular malignancy, the only solution is to prescribe the drug off-label or not at all. Tumour molecular profiling can exacerbate this dilemma. The authors of this Perspectives discuss the French AcSé Programme that aims to provide access to molecular testing and the option to receive targeted drugs outside of planned or approved marketing indications in a manner that is safe and further builds on the evidence-base for the use of such agents.
- Agnès Buzyn
- Jean-Yves Blay
- Gilles Vassal